Equities research analysts expect that American Renal Associates Holdings Inc (NYSE:ARA) will post $196.25 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for American Renal Associates’ earnings. The lowest sales estimate is $196.00 million and the highest is $196.50 million. American Renal Associates reported sales of $199.11 million in the same quarter last year, which indicates a negative year over year growth rate of 1.4%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that American Renal Associates will report full year sales of $196.25 million for the current financial year, with estimates ranging from $747.00 million to $747.20 million. For the next fiscal year, analysts expect that the business will report sales of $822.70 million per share, with estimates ranging from $820.40 million to $825.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow American Renal Associates.

American Renal Associates (NYSE:ARA) last issued its earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.03. The company had revenue of $187.71 million for the quarter, compared to the consensus estimate of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company earned $0.28 EPS.

Several analysts recently issued reports on ARA shares. Zacks Investment Research downgraded American Renal Associates from a “buy” rating to a “hold” rating in a research note on Friday, November 17th. SunTrust Banks set a $18.00 target price on American Renal Associates and gave the company a “buy” rating in a research note on Sunday, October 15th. Finally, Leerink Swann reissued an “outperform” rating and set a $17.00 target price (down previously from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.75.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its stake in American Renal Associates by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock worth $726,000 after acquiring an additional 285 shares during the last quarter. Rhumbline Advisers increased its stake in American Renal Associates by 2.7% in the 2nd quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock worth $248,000 after acquiring an additional 354 shares during the last quarter. Alliancebernstein L.P. increased its stake in American Renal Associates by 3.0% in the 2nd quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock worth $258,000 after acquiring an additional 400 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in American Renal Associates by 19.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after acquiring an additional 1,443 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in American Renal Associates by 8.8% in the 2nd quarter. Teachers Advisors LLC now owns 17,910 shares of the company’s stock worth $332,000 after acquiring an additional 1,444 shares during the last quarter. 93.27% of the stock is currently owned by institutional investors.

Shares of American Renal Associates (NYSE ARA) opened at $14.92 on Friday. The stock has a market capitalization of $451.15, a P/E ratio of 21.40, a P/E/G ratio of 1.27 and a beta of 4.29. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $24.16. The company has a debt-to-equity ratio of 3.57, a quick ratio of 1.13 and a current ratio of 1.16.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/09/analysts-expect-american-renal-associates-holdings-inc-ara-will-announce-quarterly-sales-of-196-25-million.html.

About American Renal Associates

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.